S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia to cut oil output by 1 million barrels per day to boost slumping prices
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia to cut oil output by 1 million barrels per day to boost slumping prices
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia to cut oil output by 1 million barrels per day to boost slumping prices
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia to cut oil output by 1 million barrels per day to boost slumping prices
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
NASDAQ:KALV

KalVista Pharmaceuticals (KALV) Price Target & Analyst Ratings

$10.00
-0.08 (-0.79%)
(As of 06/2/2023 ET)
Compare
Today's Range
$9.97
$10.26
50-Day Range
$6.61
$10.57
52-Week Range
$4.12
$17.06
Volume
143,163 shs
Average Volume
188,834 shs
Market Capitalization
$341.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.33

KalVista Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$19.33
93.33% Upside
High Prediction$22.00
Average Prediction$19.33
Low Prediction$16.00
TypeCurrent
6/4/22 to 6/4/23
1 Month Ago
5/5/22 to 5/5/23
3 Months Ago
3/6/22 to 3/6/23
1 Year Ago
6/4/21 to 6/4/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$19.33$19.33$20.00$47.00
Predicted Upside93.33% Upside150.00% Upside216.96% Upside210.23% Upside
Get KalVista Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.


KALV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KALV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

KalVista Pharmaceuticals Stock vs. The Competition

TypeKalVista PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.49
Consensus RatingBuyBuyHold
Predicted Upside93.33% Upside1,263.09% Upside209.76% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/21/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$22.00+168.29%
4/11/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
3/10/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$16.00+116.80%
2/3/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$30.00 ➝ $20.00+162.47%
(Data available from 6/4/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












KALV Price Target - Frequently Asked Questions

What is KalVista Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for KalVista Pharmaceuticals stock is Buy based on the current 4 buy ratings for KALV. The average twelve-month price prediction for KalVista Pharmaceuticals is $19.33 with a high price target of $22.00 and a low price target of $16.00. Learn more on KALV's analyst rating history.

Do Wall Street analysts like KalVista Pharmaceuticals more than its competitors?

Analysts like KalVista Pharmaceuticals more than other Medical companies. The consensus rating score for KalVista Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how KALV compares to other companies.

Does KalVista Pharmaceuticals's stock price have much upside?

According to analysts, KalVista Pharmaceuticals's stock has a predicted upside of 150.00% based on their 12-month price targets.

What analysts cover KalVista Pharmaceuticals?

KalVista Pharmaceuticals has been rated by Cantor Fitzgerald, HC Wainwright, and Needham & Company LLC in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:KALV) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -